SpringWorks Therapeutics (SWTX)
(Delayed Data from NSDQ)
$45.53 USD
+1.33 (3.01%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $45.55 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
SWTX 45.53 +1.33(3.01%)
Will SWTX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SWTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SWTX
Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up
SpringWorks (SWTX) Surges More Than 80% in 3 Months: Here's Why
SWTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
SpringWorks (SWTX) Falls Despite Positive Mirdametinib Study Data
Wall Street Analysts Think SpringWorks Therapeutics (SWTX) Could Surge 212%: Read This Before Placing a Bet
Other News for SWTX
SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
SpringWorks Therapeutics -- Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024